10x Genomics
289 hedge funds and large institutions have $3.87B invested in 10x Genomics in 2024 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 112 increasing their positions, 76 reducing their positions, and 42 closing their positions.
266% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $3.9M
52% more capital inflows, than outflows
Capital inflows: $764M | Capital outflows: $503M
47% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 76
36% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 42
5.95% more ownership
Funds ownership: 92.14% → 98.09% (+6%)
5% more funds holding
Funds holding: 275 → 289 (+14)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
+$98.5M |
| 2 |
Nikko Asset Management Americas
New York
|
+$58.8M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$58.8M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$46.7M |
| 5 |
Morgan Stanley
New York
|
+$43.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$98.9M |
| 2 |
JP Morgan Chase
New York
|
-$61.3M |
| 3 |
Eagle Asset Management
St Petersburg,
Florida
|
-$40.8M |
| 4 |
SRS Investment Management
New York
|
-$38.3M |
| 5 |
Brown Capital Management
Baltimore,
Maryland
|
-$37.5M |
TXG Hedge Fund Activity: Q1 2024 in Review
289 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2024, worth a combined $3.87B — down 28% from $5.37B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new TXG positions and 42 closed out — a net gain of 15 holders — while 112 added to existing stakes and 76 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $98.5M. The largest seller was Invesco, cutting an estimated $98.9M.
- 289 institutional investors held 10x Genomics (TXG) as of Q1 2024, up from 275 in Q4 2023.
- Funds reported $3.87B of 10x Genomics stock for Q1 2024, down 28% quarter-over-quarter.
- 57 funds opened new 10x Genomics positions in Q1 2024 and 42 closed out, a net change of +15 holders.
- The largest 10x Genomics buyer in Q1 2024 was ARK Investment Management, an estimated $98.5M added.
- The largest 10x Genomics seller in Q1 2024 was Invesco, an estimated $98.9M sold.
Based on aggregated 13F filings for Q1 2024.